資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/34584
|
| 標題: | Association of Gonadotropin-Releasing Hormone Therapies With Venous Thromboembolic Events in Patients With Prostate Cancer: A National Cohort Study |
| 作者: | Hong, Chon-Seng
Chen, Yi-Chen
Ho, Chung-Han
Hsieh, Kun-Lin
Chen, Michael
Shih, Jhih-Yuan
Chiang, Chun-Yen
Chen, Zhih-Cherng
Chang, Wei-Ting |
| 貢獻者: | Chi Mei Hospital
Chi Mei Hospital
Southern Taiwan University of Science & Technology
Chi Mei Hospital
National Cheng Kung University
Department of Health and Nutrition, Chia Nan University of Pharmacy & Science
Chung Hua University
Southern Taiwan University of Science & Technology
National Cheng Kung University |
| 關鍵字: | androgen-deprivation therapy
risk
epidemiology
thrombosis
agonists
disease
statins
taiwan
stroke
men |
| 日期: | 2022 |
| 上傳時間: | 2023-12-11 13:59:08 (UTC+8) |
| 出版者: | FRONTIERS MEDIA SA |
| 摘要: | Although androgen deprivation therapy (ADT) has been proposed to be associated with a higher risk of venous thromboembolisms (VTEs), whether gonadotropin-releasing hormones (GnRHs), such as both agonists and antagonists, are also associated with VTEs remain unclear. Using the Taiwan Cancer Registry (TCR) linked with the National Health Insurance Research Database, we identified patients diagnosed with prostate cancer from 2008 to 2015. Patients who received GnRH were 1:1 propensity score matched with non-GnRH users by age and cancer stage at diagnosis and clinical stage. Cox regression analysis was applied to estimate the incidences of VTEs with death as a competing event at the 5-year follow-up. The VTE incidence among GnRH users was 1.13% compared with 0.98% among non-users. After adjusting with potential confounding factors, the risk of VTEs showed borderline statistical significance among GnRH users and non-users. Notably, in the subgroup analysis among patients receiving GnRH therapy, those younger than 70 years old or at an earlier stage (stage I/II) were at a higher risk of VTEs. Different from previous studies, our findings highlighted critical concerns regarding the cardiac safety of GnRH therapies in prostate cancer patients at a relatively younger age or at an earlier stage. |
| 關聯: | FRONTIERS IN CARDIOVASCULAR MEDICINE, v.9 |
| 顯示於類別: | [保健營養系(所) ] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| cvm.2022.794310.pdf | | 504Kb | Adobe PDF | 145 | 檢視/開啟 | | index.html | | 0Kb | HTML | 368 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
